View in EDS HTML Full Text PDF Full Text

Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study.

Saved in:
Bibliographic Details
Title: Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study.
Authors: Guillén, Núria (AUTHOR), Contador, José (AUTHOR), Buongiorno, Mariateresa (AUTHOR), Álvarez, Ignacio (AUTHOR), Culell, Natalia (AUTHOR), Alcolea, Daniel (AUTHOR), Lleó, Alberto (AUTHOR), Fortea, Juan (AUTHOR), Piñol-Ripoll, Gerard (AUTHOR), Carnes-Vendrell, Anna (AUTHOR), Lourdes Ispierto, María (AUTHOR), Vilas, Dolores (AUTHOR), Puig-Pijoan, Albert (AUTHOR), Fernández-Lebrero, Aida (AUTHOR), Balasa, Mircea (AUTHOR), Sánchez-Valle, Raquel (AUTHOR), Lladó, Albert (AUTHOR)
Source: European Archives of Psychiatry & Clinical Neuroscience. Feb2025, Vol. 275 Issue 1, p257-266. 10p.
Subjects: Lewy body dementia, Alzheimer's disease, Tau proteins, Mild cognitive impairment, Frontotemporal dementia
Abstract: Core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET). Our goal was to analyze the agreement between AD CSF biomarkers and amyloid-PET in a multicenter study. Retrospective multicenter study (5 centers). Participants who underwent both CSF biomarkers and amyloid-PET scan within 18 months were included. Clinical diagnoses were made according to latest diagnostic criteria by the attending clinicians. CSF Amyloid Beta1-42 (Aβ1-42, A), phosphorliated tau 181 (pTau181, T) and total tau (tTau, N) biomarkers were considered normal (−) or abnormal (+) according to cutoffs of each center. Amyloid-PET was visually classified as positive/negative. Agreement between CSF biomarkers and amyloid-PET was analyzed by overall percent agreement (OPA). 236 participants were included (mean age 67.9 years (SD 9.1), MMSE score 24.5 (SD 4.1)). Diagnoses were mild cognitive impairment or dementia due to AD (49%), Lewy body dementia (22%), frontotemporal dementia (10%) and others (19%). Mean time between tests was 5.1 months (SD 4.1). OPA between single CSF biomarkers and amyloid-PET was 74% for Aβ1-42, 75% for pTau181, 73% for tTau. The use of biomarker ratios improved OPA: 87% for Aβ1-42/Aβ1-40 (n = 155), 88% for pTau181/Aβ1-42 (n = 94) and 82% for tTau/Aβ1-42 (n = 160). A + T + N + cases showed the highest agreement between CSF biomarkers and amyloid-PET (96%), followed by A-T-N- cases (89%). Aβ1-42/Aβ1-40 was a better marker of cerebral amyloid deposition, as identified by amyloid tracers, than Aβ1-42 alone. Combined biomarkers in CSF predicted amyloid-PET result better than single biomarkers. [ABSTRACT FROM AUTHOR]
Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 182842082
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Guillén%2C+Núria%22">Guillén, Núria</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Contador%2C+José%22">Contador, José</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Buongiorno%2C+Mariateresa%22">Buongiorno, Mariateresa</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Álvarez%2C+Ignacio%22">Álvarez, Ignacio</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Culell%2C+Natalia%22">Culell, Natalia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Alcolea%2C+Daniel%22">Alcolea, Daniel</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lleó%2C+Alberto%22">Lleó, Alberto</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fortea%2C+Juan%22">Fortea, Juan</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Piñol-Ripoll%2C+Gerard%22">Piñol-Ripoll, Gerard</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Carnes-Vendrell%2C+Anna%22">Carnes-Vendrell, Anna</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lourdes+Ispierto%2C+María%22">Lourdes Ispierto, María</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vilas%2C+Dolores%22">Vilas, Dolores</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Puig-Pijoan%2C+Albert%22">Puig-Pijoan, Albert</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fernández-Lebrero%2C+Aida%22">Fernández-Lebrero, Aida</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Balasa%2C+Mircea%22">Balasa, Mircea</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sánchez-Valle%2C+Raquel%22">Sánchez-Valle, Raquel</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lladó%2C+Albert%22">Lladó, Albert</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Archives+of+Psychiatry+%26+Clinical+Neuroscience%22">European Archives of Psychiatry & Clinical Neuroscience</searchLink>. Feb2025, Vol. 275 Issue 1, p257-266. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Lewy+body+dementia%22">Lewy body dementia</searchLink><br /><searchLink fieldCode="DE" term="%22Alzheimer's+disease%22">Alzheimer's disease</searchLink><br /><searchLink fieldCode="DE" term="%22Tau+proteins%22">Tau proteins</searchLink><br /><searchLink fieldCode="DE" term="%22Mild+cognitive+impairment%22">Mild cognitive impairment</searchLink><br /><searchLink fieldCode="DE" term="%22Frontotemporal+dementia%22">Frontotemporal dementia</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET). Our goal was to analyze the agreement between AD CSF biomarkers and amyloid-PET in a multicenter study. Retrospective multicenter study (5 centers). Participants who underwent both CSF biomarkers and amyloid-PET scan within 18 months were included. Clinical diagnoses were made according to latest diagnostic criteria by the attending clinicians. CSF Amyloid Beta1-42 (Aβ1-42, A), phosphorliated tau 181 (pTau181, T) and total tau (tTau, N) biomarkers were considered normal (−) or abnormal (+) according to cutoffs of each center. Amyloid-PET was visually classified as positive/negative. Agreement between CSF biomarkers and amyloid-PET was analyzed by overall percent agreement (OPA). 236 participants were included (mean age 67.9 years (SD 9.1), MMSE score 24.5 (SD 4.1)). Diagnoses were mild cognitive impairment or dementia due to AD (49%), Lewy body dementia (22%), frontotemporal dementia (10%) and others (19%). Mean time between tests was 5.1 months (SD 4.1). OPA between single CSF biomarkers and amyloid-PET was 74% for Aβ1-42, 75% for pTau181, 73% for tTau. The use of biomarker ratios improved OPA: 87% for Aβ1-42/Aβ1-40 (n = 155), 88% for pTau181/Aβ1-42 (n = 94) and 82% for tTau/Aβ1-42 (n = 160). A + T + N + cases showed the highest agreement between CSF biomarkers and amyloid-PET (96%), followed by A-T-N- cases (89%). Aβ1-42/Aβ1-40 was a better marker of cerebral amyloid deposition, as identified by amyloid tracers, than Aβ1-42 alone. Combined biomarkers in CSF predicted amyloid-PET result better than single biomarkers. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=182842082
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00406-023-01701-y
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 257
    Subjects:
      – SubjectFull: Lewy body dementia
        Type: general
      – SubjectFull: Alzheimer's disease
        Type: general
      – SubjectFull: Tau proteins
        Type: general
      – SubjectFull: Mild cognitive impairment
        Type: general
      – SubjectFull: Frontotemporal dementia
        Type: general
    Titles:
      – TitleFull: Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Guillén, Núria
      – PersonEntity:
          Name:
            NameFull: Contador, José
      – PersonEntity:
          Name:
            NameFull: Buongiorno, Mariateresa
      – PersonEntity:
          Name:
            NameFull: Álvarez, Ignacio
      – PersonEntity:
          Name:
            NameFull: Culell, Natalia
      – PersonEntity:
          Name:
            NameFull: Alcolea, Daniel
      – PersonEntity:
          Name:
            NameFull: Lleó, Alberto
      – PersonEntity:
          Name:
            NameFull: Fortea, Juan
      – PersonEntity:
          Name:
            NameFull: Piñol-Ripoll, Gerard
      – PersonEntity:
          Name:
            NameFull: Carnes-Vendrell, Anna
      – PersonEntity:
          Name:
            NameFull: Lourdes Ispierto, María
      – PersonEntity:
          Name:
            NameFull: Vilas, Dolores
      – PersonEntity:
          Name:
            NameFull: Puig-Pijoan, Albert
      – PersonEntity:
          Name:
            NameFull: Fernández-Lebrero, Aida
      – PersonEntity:
          Name:
            NameFull: Balasa, Mircea
      – PersonEntity:
          Name:
            NameFull: Sánchez-Valle, Raquel
      – PersonEntity:
          Name:
            NameFull: Lladó, Albert
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: Feb2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 09401334
          Numbering:
            – Type: volume
              Value: 275
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: European Archives of Psychiatry & Clinical Neuroscience
              Type: main
ResultId 1